During the corresponding time, Voyager Therapeutics Inc saw a revenue deteriorated by -39.13 % year on year, sequentially revenue grew by 22.06 %. While revenue at the Voyager Therapeutics Inc 's corporate clients
Voyager Therapeutics Inc's Comment on Sales, Marketing and Customers
The company operates in the gene therapy, non-viral therapeutics, and biological products markets, with a focus on neurogenetic medicines and gene therapy. It manufactures AAV gene therapy materials for preclinical research, clinical, and commercial use through proprietary processes and third-party contract manufacturers. The company does not intend to establish its own clinical or commercial manufacturing facilities but manages contract manufacturers with experienced personnel. It seeks to protect its proprietary technology and maintain patent rights to support its business development in neurogenetic medicines and gene therapy. The company expects its product candidates to compete based on efficacy, safety, convenience, price, and reimbursement availability.
The Frontier of Genetic Medicine: Voyager s Next-Generation CNS Capsids and the Future of Neurological Therapies In the rapidly evolving field of genetic medicine, innovative breakthroughs are frequently redefining possibilities for therapeutic interventions, particularly in the realm of neurodegenerative diseases. At the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), an oral presentation highlighted a pioneering development in the form of Voyager Therapeutics’ next-generation central nervous system (CNS) capsids. Among the notable revelations was a transformative tau silencing gene therapy treatment, VY1706, showcasing a striking capability of achieving up to 73% knockdown o...
Voyager Therapeutics, a prominent company in the field of gene therapy, has announced the selection of VY1706 as their lead candidate for a promising tau silencing gene therapy aimed at treating Alzheimer s disease. This decision marks a significant step forward in addressing one of the most challenging and prevalent neurodegenerative conditions impacting millions of individuals worldwide.Understanding the Mechanism: Targeting Tau ProteinAlzheimer s disease is characterized by the progressive degeneration of neurons, leading to cognitive decline and memory impairment. A key pathological hallmark of this disease is the abnormal accumulation of tau protein in the brain, which disrupts normal cellular function....
Reversing the Tide of Alzheimer s: Voyager Therapeutics Initiates Promising Phase 1a Trial with VY-TAU01, a Novel Anti-Tau AntibodyLEXINGTON, Mass., May 16, 2024 - In the relentless pursuit of innovative neurogenetic treatments, Voyager Therapeutics, Inc. (Nasdaq: VYGR) has crossed a significant milestone. The company proudly announced today that the first participants have been dosed in a groundbreaking Phase 1a single ascending dose (SAD) trial of VY-TAU01. Developed as an investigational anti-tau antibody, VY-TAU01 aims to obstruct the progress of pathological tau, providing a potential breakthrough in the treatment of Alzheimer s disease.Alzheimer s disease, a progressive neurodegenerative disorder, affe...
Gene therapies have emerged as a promising frontier in the healthcare industry, offering potential cures for previously untreatable diseases. Voyager Therapeutics, a renowned clinical-stage gene therapy company, has recently entered a transformative Capsid License Agreement and Strategic Collaboration with Novartis, a global leader in gene therapy. This groundbreaking collaboration aims to propel the discovery and development of novel gene therapies for Huntington s disease and spinal muscular atrophy (SMA), two devastating genetic disorders.Voyager Therapeutics brings to the table its cutting-edge expertise and pioneering technology that leverages adeno-associated virus (AAV) vectors to safely deliver thera...
Voyager Therapeutics Inc’s Comment on Sales, Marketing and Customers
The company operates in the gene therapy, non-viral therapeutics, and biological products markets, with a focus on neurogenetic medicines and gene therapy. It manufactures AAV gene therapy materials for preclinical research, clinical, and commercial use through proprietary processes and third-party contract manufacturers. The company does not intend to establish its own clinical or commercial manufacturing facilities but manages contract manufacturers with experienced personnel. It seeks to protect its proprietary technology and maintain patent rights to support its business development in neurogenetic medicines and gene therapy. The company expects its product candidates to compete based on efficacy, safety, convenience, price, and reimbursement availability.
Sources:
Voyager Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Voyager Therapeutics Inc’s corporate clients.
For your research, we’ve provided 9 tables on Voyager Therapeutics Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
181.93 %